Let's Talk About SACT

In this episode, we are joined by Melanie Dalby. We talk about publishing manuscripts. We discuss how to develop a publishable idea, study design and statistics, choosing the right journal, writing a manuscript, and navigating submission and peer review. Melanie also shares practical advice for pharmacy professionals looking to publish their work, including some of the common pitfalls to avoid and tips for first-time authors.

Disclaimer: The views and opinions expressed during this episode are those of the individual speakers and are shared in their personal capacity. They do not necessarily reflect the views, positions, or policies of the companies with which the speakers are affiliated. In this episode we are joined by Poonam Dhokia, Dolapo Sanni and Zsofia Nemeth. We explore the pharmaceutical industry from the perspective of working across medical affairs, clinical research and strategic roles. We discuss how the industry is structured, the importance of medical–commercial separation, clinical trials, the role of Medical Science Liaisons, and how collaboration between the NHS and pharmaceutical companies can improve research, service development and ultimately patient care. Along the way, we challenge common misconceptions about working in pharma and share practical advice for healthcare professionals on building effective, ethical partnerships with industry.

In this episode we are joined by Nikita Ponda. We discuss the pharmacist role in a melanoma charity, we discuss TrialFinder, developments in melanoma and much more.

In this episode we are joined by Dani Binnington, founder of Menopause and Cancer (https://menopauseandcancer.org/). We discuss Dani's journey as a cancer patient going through menopause, guidance and best practice. Link for Non-hormonal-based treatments for menopausal symptoms guidance: https://thebms.org.uk/wp-content/uploads/2025/11/04-BMS-ConsensusStatement-Non-hormonal-based-treatments-for-menopausal-symptoms-NOV2025-C.pdf

In this episode we are joined by Alice Tew and Meera Desai. We discuss the history of the immunotherapy group, how and why it was established and how its work has evolved. We explore key projects including improving equity of access to second-line agents, the development of immunotherapy monographs, upcoming priorities for the group and much more.